Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Fizazi, Karim" or (type any "bookEditor issueEditor" and editor="Fizazi, Karim")

Add to list
- Journal Article
- A1
- open access
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Matthew R. Smith, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Evgeny Kopyltsov, Chandler H. Park, Boris Alekseev, Álvaro Montesa-Pino, et al.

(2022) NEW ENGLAND JOURNAL OF MEDICINE. 386(12). p.1132-1142
Add to list
Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey (UGent) , Nabil Adra, Mark Salvati, Shirley Poon, et al.

(2020) JOURNAL FOR IMMUNOTHERAPY OF CANCER. 8(Supplement: 3). p.A207-A208
Add to list
- Conference Paper
- C3
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran, Lisa Horvath, Matthew Rettig, Karim Fizazi, Martijn P. Lolkema, Tanya B. Dorff, Richard Greil, Jean-Pascal H. Machiels, Karen A. Autio, Sylvie Rottey (UGent) , et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(15).
Add to list
- Journal Article
- A1
- open access
Management of patients with advanced prostate cancer : report of the Advanced Prostate Cancer Consensus Conference 2019

Silke Gillessena, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Alberto Bossi, Alberto Briganti, Rob G. Bristow, Kim N. Chi, Noel Clarke, et al.

(2020) EUROPEAN UROLOGY. 77(4). p.508-547
Add to list
- Journal Article
- A1
- open access
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, et al.

(2019) NEW ENGLAND JOURNAL OF MEDICINE. 381(26). p.2506-2518
Add to list
Consensus on molecular imaging and theranostics in prostate cancer

Stefano Fanti, Silvia Minozzi, Gerald Antoch, Ian Banks, Alberto Briganti, Ignasi Carrio, Arturo Chiti, Noel Clarke, Matthias Eiber, Johann De Bono, et al.

(2018) LANCET ONCOLOGY. 19(12). p.E696-E708
Add to list
- Journal Article
- A1
- open access
Management of patients with advanced prostate cancer : the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, Daniel Castellano, Byung Ha Chung, Noel Clarke, et al.

(2018) EUROPEAN UROLOGY. 73(2). p.178-211
Add to list
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J Ryan, Matthew R Smith, Karim Fizazi, Fred Saad, Peter F A Mulders, Cora N Sternberg, Kurt Miller, Christopher J Logothetis, Neal D Shore, Eric J Small, et al.

(2015) LANCET ONCOLOGY. 16(2). p.152-160
Add to list
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

Stephen Harland, John Staffurth, Arturo Molina, Yanni Hao, Dennis D. Gagnon, Cora N. Sternberg, David Cella, Karim Fizazi, Christopher J. Logothetis, Thian Kheoh, et al.

(2013) EUROPEAN JOURNAL OF CANCER. 49(17). p.3648-3657
Add to list
- Journal Article
- A1
- open access
Abiraterone in metastatic prostate cancer without previous chemotherapy

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono, Arturo Molina, Christopher J. Logothetis, Paul de Souza, Karim Fizazi, Paul Mainwaring, Josep M. Piulats, Siobhan Ng, et al.

(2013) NEW ENGLAND JOURNAL OF MEDICINE. 368(2). p.138-148

Academic Bibliography

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Phase 1 study of AMG 160, a half-life extended BITE (R) (bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Management of patients with advanced prostate cancer : report of the Advanced Prostate Cancer Consensus Conference 2019

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Consensus on molecular imaging and theranostics in prostate cancer

Management of patients with advanced prostate cancer : the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302) : final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

Abiraterone in metastatic prostate cancer without previous chemotherapy

Contents

Support

Contact